The DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationCalcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Cortisone in Ulcerative Colitis
Truelove, S. C., & Witts, L. J. (1955) · BMJ · doi:10.1136/bmj.2.4947.1041 · Cited by 2,767
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Cited by
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Management of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Self-citationTofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
Relling, M. V., Schwab, M., Whirl‐Carrillo, M., Suarez‐Kurtz, G., Pui, C., Stein, C. M., Moyer, A. M., Evans, W. E., Klein, T. E., Antillon‐Klussmann, F. G., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1304 · Cited by 682
Treatment of Inflammatory Bowel Disease: A Comprehensive Review
Cai, Z., Wang, S., & Li, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.765474 · Cited by 675
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Gisbert, J. P., & Panés, J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.88 · Cited by 664
European evidence-based Consensus on the management of ulcerative colitis: Current management
Travis, S. P. L., Stange, E. F., Lémann, M., Øresland, T., Bemelman, W. A., Chowers, Y., Colombel, J. F., D'Haens, G., Ghosh, S., Marteau, P., et al. (2008) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2007.11.002 · Cited by 558
A comprehensive review and update on Crohn's disease
Gajendran, M., Loganathan, P., Catinella, A. P., & Hashash, J. G. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2017.07.001 · Cited by 550
Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30570-6 · Cited by 451
Bressler, B., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., Panaccione, R., Steinhart, A. H., Tse, F., Feagan, B., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.001 · Cited by 413
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
Coskun, M., Salem, M., Pedersen, J., & Nielsen, O. H. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.06.007 · Cited by 325
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
Sandborn, W. J., Feagan, B. G., Loftus, E. V., Peyrin-Biroulet, L., Van Assche, G., D’Haens, G., Schreiber, S., Colombel, J.-F., Lewis, J. D., Ghosh, S., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.047 · Cited by 322
“Currently approved therapies, including corticosteroids, immunosuppressants, and biologic agents, are not effective in some patients and may be associated with adverse effects that limit their use.(4,5) There remains an unmet need for additional targeted therapies for CD that provide short- and long-term benefits as m…”
BackgroundAn Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Talley, N. J., Abreu, M. T., Achkar, J.-P., Bernstein, C. N., Dubinsky, M. C., Hanauer, S. B., Kane, S. V., Sandborn, W. J., Ullman, T. A., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.58 · Cited by 310
Self-citationA Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Wang, W., Niezychowski, W., Vermeire, S. A. R. A., Dewit, O., Peeters, H., Stehlik, J., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.029 · Cited by 300
Clinical Pharmacokinetics and Use??of??Infliximab
Klotz, U., Teml, A., & Schwab, M. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746080-00002 · Cited by 261
Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa
Collnot, E.-M., Ali, H., & Lehr, C.-M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.028 · Cited by 254
Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review
Gisbert, J. P., & Gomolln, F. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01848.x · Cited by 253
Common Misconceptions in the Diagnosis and Management of Anemia in Inflammatory Bowel Disease
Gisbert, J. P., & Gomollón, F. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01846.x · Cited by 230
Influences and impact of anxiety and depression in the setting of inflammatory bowel disease
Navabi, S., Gorrepati, V. S., Yadav, S., Chintanaboina, J., Maher, S., Demuth, P., Stern, B., Stuart, A., Tinsley, A., Clarke, K., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy143 · Cited by 172
Nitrated oleic acid up-regulates PPARγ and attenuates experimental inflammatory bowel disease
Borniquel, S., Jansson, E. Å., Cole, M. P., Freeman, B. A., & Lundberg, J. O. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.014 · Cited by 92
Oliva‐Hemker, M. M., Abadom, V., Cuffari, C., & Thompson, R. E. (2007) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31802b320e · Cited by 59
Metadata
- Authors
- Lichtenstein, G. R., Abreu, M. T., Cohen, R., & Tremaine, W.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 130
- Issue
- 3
- Pages
- 940-987
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2074509533
- Cited by
- 417
- References
- 200
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.